Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01

Contributed by: Business Wire

Logo

Tags

Science

Research

Pharmaceutical

Oncology

General Health

Health

FDA

Clinical Trials

Curatis Holding AG

More Like This

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3

Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues

Curatis discloses Corticorelin as active substance of C-PTBE-01

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy